A systematic review of the evidence for deprescribing interventions among older people living with frailty
A systematic review of the evidence for deprescribing interventions among older people living with frailty
Background: older people living with frailty are often exposed to polypharmacy and potential harm from medications. Targeted deprescribing in this population represents an important component of optimizing medication. This systematic review aims to summarise the current evidence for deprescribing among older people living with frailty.
Methods: the literature was searched using Medline, Embase, CINAHL, PsycInfo, Web of Science, and the Cochrane library up to May 2020. Interventional studies with any design or setting were included if they reported deprescribing interventions among people aged 65+ who live with frailty identified using reliable measures. The primary outcome was safety of deprescribing; whereas secondary outcomes included clinical outcomes, medication-related outcomes, feasibility, acceptability and cost-related outcomes. Narrative synthesis was used to summarise findings and study quality was assessed using Joanna Briggs Institute checklists.
Results: two thousand three hundred twenty-two articles were identified and six (two randomised controlled trials) were included with 657 participants in total (mean age range 79–87 years). Studies were heterogeneous in their designs, settings and outcomes. Deprescribing interventions were pharmacist-led (n = 3) or multidisciplinary team-led (n = 3). Frailty was identified using several measures and deprescribing was implemented using either explicit or implicit tools or both. Three studies reported safety outcomes and showed no significant changes in adverse events, hospitalisation or mortality rates. Three studies reported positive impact on clinical outcomes including depression, mental health status, function and frailty; with mixed findings on falls and cognition; and no significant impact on quality of life. All studies described medication-related outcomes and reported a reduction in potentially inappropriate medications and total number of medications per-patient. Feasibility of deprescribing was reported in four studies which showed that 72–91% of recommendations made were implemented. Two studies evaluated and reported the acceptability of their interventions and further two described cost saving.
Conclusion: there is a paucity of research about the impact of deprescribing in older people living with frailty. However, included studies suggest that deprescribing could be safe, feasible, well tolerated and can lead to important benefits. Research should now focus on understanding the impact of deprescribing on frailty status in high risk populations.
Deprescribing, Frailty, Inappropriate medications, medication review, polypharmacy
Ibrahim, Kinda
54f027ad-0599-4dd4-bdbf-b9307841a294
Cox, Natalie
dfdfbc5f-41b8-4329-a4b5-87b6e93aa09e
Stevenson, Jennifer
7aa817a5-b81f-4720-ad08-b2d117dd5127
Lim, Stephen
dd2bfbd7-7f74-4365-b77e-9989f6408ddc
Fraser, Simon
135884b6-8737-4e8a-a98c-5d803ac7a2dc
Roberts, Helen
5ea688b1-ef7a-4173-9da0-26290e18f253
17 April 2021
Ibrahim, Kinda
54f027ad-0599-4dd4-bdbf-b9307841a294
Cox, Natalie
dfdfbc5f-41b8-4329-a4b5-87b6e93aa09e
Stevenson, Jennifer
7aa817a5-b81f-4720-ad08-b2d117dd5127
Lim, Stephen
dd2bfbd7-7f74-4365-b77e-9989f6408ddc
Fraser, Simon
135884b6-8737-4e8a-a98c-5d803ac7a2dc
Roberts, Helen
5ea688b1-ef7a-4173-9da0-26290e18f253
Ibrahim, Kinda, Cox, Natalie, Stevenson, Jennifer, Lim, Stephen, Fraser, Simon and Roberts, Helen
(2021)
A systematic review of the evidence for deprescribing interventions among older people living with frailty.
BMC Geriatrics, 21 (1), [258].
(doi:10.1186/s12877-021-02208-8).
Abstract
Background: older people living with frailty are often exposed to polypharmacy and potential harm from medications. Targeted deprescribing in this population represents an important component of optimizing medication. This systematic review aims to summarise the current evidence for deprescribing among older people living with frailty.
Methods: the literature was searched using Medline, Embase, CINAHL, PsycInfo, Web of Science, and the Cochrane library up to May 2020. Interventional studies with any design or setting were included if they reported deprescribing interventions among people aged 65+ who live with frailty identified using reliable measures. The primary outcome was safety of deprescribing; whereas secondary outcomes included clinical outcomes, medication-related outcomes, feasibility, acceptability and cost-related outcomes. Narrative synthesis was used to summarise findings and study quality was assessed using Joanna Briggs Institute checklists.
Results: two thousand three hundred twenty-two articles were identified and six (two randomised controlled trials) were included with 657 participants in total (mean age range 79–87 years). Studies were heterogeneous in their designs, settings and outcomes. Deprescribing interventions were pharmacist-led (n = 3) or multidisciplinary team-led (n = 3). Frailty was identified using several measures and deprescribing was implemented using either explicit or implicit tools or both. Three studies reported safety outcomes and showed no significant changes in adverse events, hospitalisation or mortality rates. Three studies reported positive impact on clinical outcomes including depression, mental health status, function and frailty; with mixed findings on falls and cognition; and no significant impact on quality of life. All studies described medication-related outcomes and reported a reduction in potentially inappropriate medications and total number of medications per-patient. Feasibility of deprescribing was reported in four studies which showed that 72–91% of recommendations made were implemented. Two studies evaluated and reported the acceptability of their interventions and further two described cost saving.
Conclusion: there is a paucity of research about the impact of deprescribing in older people living with frailty. However, included studies suggest that deprescribing could be safe, feasible, well tolerated and can lead to important benefits. Research should now focus on understanding the impact of deprescribing on frailty status in high risk populations.
Text
s12877-021-02208-8
- Version of Record
Text
Deprescribing systematic review
More information
Accepted/In Press date: 8 April 2021
e-pub ahead of print date: 17 April 2021
Published date: 17 April 2021
Additional Information:
Funding Information:
Authors did not receive funding to complete this review. However, authors receive support from the National Institute of Health Research (NIHR). H.C.R, SF, SL and K. I receive support from the NIHR Applied Research Collaboration (ARC) Wessex. KI, N.J.C and H.C.R receive support from the NIHR Southampton Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
Keywords:
Deprescribing, Frailty, Inappropriate medications, medication review, polypharmacy
Identifiers
Local EPrints ID: 448725
URI: http://eprints.soton.ac.uk/id/eprint/448725
ISSN: 1471-2318
PURE UUID: 5a4c24e3-1277-4eb4-8d09-8c33837fed7b
Catalogue record
Date deposited: 04 May 2021 16:37
Last modified: 12 Nov 2024 03:15
Export record
Altmetrics
Contributors
Author:
Natalie Cox
Author:
Jennifer Stevenson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics